Tissue Regenix Group plc (TRX) ORD GBP0.001
Sell:40.00pBuy:41.00p
No change
- This stock can be held in a
Stocks and Shares ISANo changeNo changeCompany Information
About this company
Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.
Key people
Key facts
- EPICTRX
- LocationUnited Kingdom
- SectorTechnology
- IndustrySoftware & Programming
- ISINGB00BNTXR104
- Market cap£28.85m
- Employees76
- Shares in issue71.40m
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.